

PRECISION OPTICS CORPORATION, INC.
Form 10-Q
February 12, 2019
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2018

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-10647

PRECISION OPTICS CORPORATION, INC.

(Exact name of registrant as specified in its charter)

Massachusetts

(State or other jurisdiction of incorporation or organization)

04-2795294

(I.R.S. Employer Identification No.)

22 East Broadway, Gardner, Massachusetts 01440-3338

(Address of principal executive offices) (Zip Code)

(978) 630-1800

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the issuer's common stock, par value \$0.01 per share, at February 12, 2019 was 11,997,139 shares.

PRECISION OPTICS CORPORATION, INC.

Table of Contents

	Page
<u>PART I — FINANCIAL INFORMATION</u>	3
<u>Item 1. Financial Statements</u>	3
<u>Consolidated Balance Sheets at December 31, 2018 and June 30, 2018</u>	3
<u>Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2018 and 2017</u>	4
<u>Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended December 31, 2018 and 2017</u>	5
<u>Consolidated Statements of Cash Flows for the Three and Six Months Ended December 31, 2018 and 2017</u>	6
<u>Notes to Consolidated Financial Statements</u>	7
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	11
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	15
<u>Item 4. Controls and Procedures</u>	15
<u>PART II — OTHER INFORMATION</u>	16
<u>Item 1. Legal Proceedings</u>	16
<u>Item 1A. Risk Factors</u>	16
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	16
<u>Item 3. Defaults Upon Senior Securities</u>	16
<u>Item 4. Mine Safety Disclosures (Not applicable.)</u>	16
<u>Item 5. Other Information</u>	16
<u>Item 6. Exhibits</u>	17

PART I. FINANCIAL INFORMATION**Item 1. Financial Statements.****PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS****(UNAUDITED)**

	December 31, 2018	June 30, 2018
ASSETS		
CURRENT ASSETS		
Cash and Cash Equivalents	\$ 1,744,644	\$ 402,738
Accounts Receivable, net	728,636	796,923
Inventories, net	1,095,525	1,144,068
Prepaid Expenses	136,517	70,991
Total Current Assets	3,705,322	2,414,720
PROPERTY AND EQUIPMENT		
Machinery and Equipment	2,574,579	2,511,638
Leasehold Improvements	566,839	553,596
Furniture and Fixtures	148,303	148,303
	3,289,721	3,213,537
Less: Accumulated Depreciation and Amortization	(3,178,645)	(3,164,051)
Net Fixed Assets	111,076	49,486
Patents, net	46,007	47,275
TOTAL ASSETS	\$ 3,862,405	\$ 2,511,481
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Current Portion of Capital Lease Obligation	\$ 9,262	\$ 8,962
Accounts Payable	752,020	703,538
Customer Advances	294,650	857,842

Edgar Filing: PRECISION OPTICS CORPORATION, INC. - Form 10-Q

Accrued Employee Compensation	228,314	238,590
Accrued Professional Services	74,250	98,000
Accrued Warranty Expense	25,000	25,000
Other Accrued Liabilities	–	912
Total Current Liabilities	1,383,496	1,932,844
Capital Lease Obligation, net of current portion	9,894	14,601
STOCKHOLDERS' EQUITY		
Common Stock, \$0.01 par value - Authorized - 50,000,000 shares; Issued and Outstanding – 11,897,139 shares at December 31, 2018 and 10,197,139 shares at June 30, 2018	118,972	101,972
Additional Paid-in Capital	47,797,398	45,484,186
Accumulated Deficit	(45,447,355)	(45,022,122)
Total Stockholders' Equity	2,469,015	564,036
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$3,862,405	\$2,511,481

The accompanying notes are an integral part of these consolidated interim financial statements.

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF OPERATIONS****FOR THE THREE AND SIX MONTHS ENDED****December 31, 2018 AND 2017****(UNAUDITED)**

	Three Months Ended December 31,		Six Months Ended December 31,	
	2018	2017	2018	2017
Revenues	\$1,477,851	\$812,773	\$3,037,309	\$1,841,519
Cost of Goods Sold	1,122,129	512,551	2,219,080	1,154,555
Gross Profit	355,722	300,222	818,229	686,964
Research and Development Expenses, net	125,413	90,031	226,211	208,458
Selling, General and Administrative Expenses	355,916	270,035	1,016,405	566,619
Total Operating Expenses	481,329	360,066	1,242,616	775,077
Operating Loss	(125,607)	(59,844)	(424,387)	(88,113)
Interest Expense	(341)	(482)	(846)	(998)
Net Loss	\$(125,948)	\$(60,326)	\$(425,233)	\$(89,111)
Loss Per Share:				
Basic	\$(0.01)	\$(0.01)	\$(0.04)	\$(0.01)
Diluted	\$(0.01)	\$(0.01)	\$(0.04)	\$(0.01)
Weighted Average Common Shares Outstanding:				
Basic	11,618,878	9,979,197	10,940,074	9,543,810
Diluted	11,618,878	9,979,197	10,940,074	9,543,810

The accompanying notes are an integral part of these consolidated interim financial statements.

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY****FOR THE THREE AND SIX MONTHS ENDED****December 31, 2018 AND 2017****(UNAUDITED)**

	Six Month Period Ended December 31, 2018				Total
	Number of	Common	Additional	Accumulated	Stockholders'
	Shares	Stock	Paid-in	Deficit	Equity
			Capital		
Balance, July 1, 2018	10,197,139	\$101,972	\$45,484,186	\$(45,022,122)	\$ 564,036
Stock-based compensation	—	—	342,984	—	342,984
Issuance of common stock for services	100,000	1,000	(1,000)	—	—
Net loss	—	—	—	(299,285)	(299,285)
Balance, September 30, 2018	10,297,139	102,972	45,826,170	(45,321,407)	607,735
Proceeds from private placement of common stock, net of issuance costs of \$23,000	1,600,000	16,000	1,961,000	—	1,977,000
Stock-based compensation	—	—	10,228	—	10,228
Net loss	—	—	—	(125,948)	(125,948)
Balance, December 31, 2018	11,897,139	\$118,972	\$47,797,398	\$(45,447,355)	\$ 2,469,015

	Six Month Period Ended December 31, 2017				Total
	Number of	Common	Additional	Accumulated	Stockholders'
	Shares	Stock	Paid-in	Deficit	Equity
			Capital		
Balance, July 1, 2017	8,872,916	\$88,729	\$45,140,383	\$(44,670,732)	\$ 558,380
Proceeds from private placement of common stock, net of issuance costs of \$2,963	555,556	5,556	241,482	—	247,038
Stock-based compensation	—	—	26,057	—	26,057
Net loss	—	—	—	(28,785)	(28,785)
Balance, September 30, 2017	9,428,472	94,285	45,407,922	(44,699,517)	802,690

Edgar Filing: PRECISION OPTICS CORPORATION, INC. - Form 10-Q

Proceeds from exercise of stock purchase warrants	666,667	6,667	–	–	6,667
Stock-based compensation	–	–	6,971	–	6,971
Net loss	–	–	–	(60,326)	(60,326)
Balance, December 31 , 2017	10,095,139	\$ 100,952	\$ 45,414,893	\$(44,759,843)	\$ 756,002

The accompanying notes are an integral part of these consolidated interim financial statements.

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES**CONSOLIDATED STATEMENTS OF CASH FLOWS****FOR THE SIX MONTHS ENDED****December 31, 2018 AND 2017****(UNAUDITED)**

	Six Months Ended December 31,	
	2018	2017
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Loss	\$(425,233)	\$(89,111)
Adjustments to Reconcile Net Loss to Net Cash Provided From (Used In) Operating Activities -		
Depreciation and Amortization	15,862	15,804
Stock-based Compensation Expense	353,212	33,028
Non-cash Consulting Expense	-	(3,387)
Changes in Operating Assets and Liabilities -		
Accounts Receivable, net	68,287	(284,604)
Inventories, net	48,543	67,656
Prepaid Expenses	(65,526)	(22,447)
Accounts Payable	48,482	41,586
Customer Advances	(563,192)	283,152
Accrued Liabilities	(57,938)	26,318
Net Cash Provided From (Used In) Operating Activities	(577,503)	67,995
CASH FLOWS FROM INVESTING ACTIVITIES:		
Additional Patent Costs	-	(17,189)
Purchases of Property and Equipment	(76,184)	-
Net Cash Used In Investing Activities	(76,184)	(17,189)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Payment of Capital Lease Obligation	(4,407)	(4,127)
Gross Proceeds from Private Placement of Common Stock	2,000,000	210,001
Gross Proceeds from Exercise of Stock Purchase Warrants	-	6,667
Net Cash Provided From Financing Activities	1,995,593	212,541
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,341,906	263,347
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	402,738	118,405

CASH AND CASH EQUIVALENTS, END OF PERIOD	\$1,744,644	\$381,752
--	-------------	-----------

SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING
ACTIVITIES:

Issuance of Common Stock in Settlement of Accounts Payable	\$-	\$40,000
Offering Costs Included in Current Liabilities	\$23,000	\$2,963

The accompanying notes are an integral part of these consolidated interim financial statements.

PRECISION OPTICS CORPORATION, INC.

NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Operations

The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly-owned subsidiaries (the "Company"). All significant intercompany accounts and transactions have been eliminated in consolidation.

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the second quarter and six months of the Company's fiscal year 2019. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company's consolidated financial statements for the year ended June 30, 2018, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company's 2018 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 27, 2018.

Use of Estimates

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Revenue Recognition

On July 1, 2018, the Company adopted ASU 2014-09 Revenue from Contracts with Customers (ASC 606) using the modified retrospective method for contracts that were not completed as of July 1, 2018, whereby revenues are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration the Company expects to receive in exchange for satisfying the performance obligations. Most of the Company's products and services are marketed to medical device companies almost exclusively in the United States. Products and services are primarily transferred to customers at a point in time based upon when services are performed or product is shipped.

Revenues represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Other selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of our revenues. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenues.

The Company disaggregates revenues by product and service types as it believes it best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors.

	Three Months Ended December 31,		Six Months Ended December 31,	
	2018	2017	2018	2017
Engineering Design Services	\$318,741	\$342,855	\$830,639	\$762,779
Optical Components	225,967	225,595	524,024	669,186
Medical Device Products and Assemblies	933,143	244,323	1,682,646	409,554
Total Revenues	\$1,477,851	\$812,773	\$3,037,309	\$1,841,519

Contract Assets and Liabilities

The nature of the Company's products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company's costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of December 31, 2018, there were no contract assets recorded in the Company's Consolidated Balance Sheets.

The Company's contract liabilities arise as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of the Company's performance obligations. The Company generally satisfies performance obligations within one year from the contract inception date. As of July 1, 2018, contract liabilities were \$857,842, which were recorded as customer advances in the Company's Consolidated Balance Sheets, \$192,722 and \$674,360 of which was recognized in sales during the three and six months ended December 31, 2018, respectively. As of December 31, 2018, contract liabilities recorded as customer advances were \$294,650.

Income (Loss) Per Share

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three and six months ended December 31, 2018 and 2017, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in these periods.

The following is the calculation of loss per share for the three and six months ended December 31, 2018 and 2017:

	Three Months Ended December 31,		Six Months Ended December 31,	
	2018	2017	2018	2017
Net Income (Loss) - Basic and Diluted	\$(125,948)	\$(60,326)	\$(425,233)	\$(89,111)
Basic and Dilutive Weighted Average Shares Outstanding	11,618,878	9,979,197	10,940,074	9,543,810
Loss Per Share - Basic and Diluted	\$(0.01)	\$(0.01)	\$(0.04)	\$(0.01)

The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 1,493,200 and 1,708,867 for the three months ended December 31, 2018 and 2017, respectively, and approximately 1,493,200 and 4,732,960 for the six months ended December 31, 2018 and 2017, respectively.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.

2. INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out) or market and consisted of the following:

	December 31, 2018	June 30, 2018
Raw Materials	\$482,553	\$500,908
Work-In-Progress	407,619	434,536
Finished Goods	205,353	208,624
Total Inventories	\$1,095,525	\$1,144,068

3. CAPITAL LEASE OBLIGATION

The Company entered into a five-year capital lease obligation in January 2016 for the acquisition of manufacturing equipment totaling \$51,252. At December 31, 2018, future minimum lease payments under the capital lease obligation are as follows:

Fiscal Year Ending June 30:	Amount
2019	\$5,126
2020	10,250
2021	5,126
Total minimum payments	20,502
Less: amount representing interest	1,346
Present value of minimum lease payments	19,156
Less: current portion	9,262
	\$9,894

4. STOCK-BASED COMPENSATION

The following table summarizes stock-based compensation expense for the three and six months ended December 31, 2018 and 2017:

	Three Months		Six Months	
	Ended December 31,		Ended December 31,	
	2018	2017	2018	2017
Cost of Goods Sold	\$-	\$-	\$-	\$8,669
Research and Development	2,411	320	4,822	7,012
Selling, General and Administrative	7,817	6,651	348,390	17,347
Stock Based Compensation Expense	\$10,228	\$6,971	\$353,212	\$33,028

No compensation has been capitalized because such amounts would have been immaterial.

The following tables summarize stock option activity for the six months ended December 31, 2018:

Options Outstanding

	Number of Shares	Weighted Average Exercise Price	Weighted Average Contractual Life
Outstanding at June 30, 2018	1,055,700	\$0.76	6.13 years
Granted	450,000		
Expired or Cancelled	(13,700)		
Outstanding at December 31, 2018	1,492,000	\$0.75	6.83 years

Information related to the stock options outstanding as of December 31, 2018 is as follows:

Range of Exercise Prices	Number of Shares	Weighted-Average Remaining Contractual Life (years)	Weighted-Average Exercise Price	Exercisable Number of Shares	Exercisable Weighted-Average Exercise Price
\$0.27	40,000	2.54	\$ 0.27	40,000	\$ 0.27
\$0.40	15,000	8.33	\$ 0.40	10,000	\$ 0.40
\$0.48	60,000	7.25	\$ 0.48	60,000	\$ 0.48
\$0.50	100,000	6.47	\$ 0.50	100,000	\$ 0.50
\$0.55	42,000	5.31	\$ 0.55	37,000	\$ 0.55
\$0.64	25,000	8.86	\$ 0.64	15,000	\$ 0.64
\$0.70	100,000	9.59	\$ 0.70	33,333	\$ 0.70
\$0.73	853,000	7.70	\$ 0.73	658,000	\$ 0.73
\$0.85	9,000	4.01	\$ 0.85	9,000	\$ 0.85
\$0.90	9,000	5.01	\$ 0.90	9,000	\$ 0.90
\$0.95	30,000	5.53	\$ 0.95	30,000	\$ 0.95
\$1.20	207,800	3.17	\$ 1.20	207,800	\$ 1.20
\$1.35	1,200	0.90	\$ 1.35	1,200	\$ 1.35
\$0.27–\$1.35	1,492,000	6.83	\$ 0.75	1,210,333	\$ 0.76

The aggregate intrinsic value of the Company's "in-the-money" outstanding and exercisable options as of December 31, 2018 was \$891,580 and \$711,496, respectively.

Common Stock Award

On August 2, 2018, the Company awarded its Chief Executive Officer 300,000 shares of common stock for services performed through June 30, 2018. The fair market value of the 300,000 shares on the award date equal to \$210,000 has been recorded as general and administrative stock-based compensation expense in the quarter ended September 30, 2018. As of December 31, 2018, 100,000 shares have been issued. Another 100,000 shares were issued on January 1, 2019, and the remaining 100,000 shares will be issued on January 1, 2020.

5. SALE OF STOCK

On October 16, 2018, the Company entered into agreements with accredited investors for the sale and purchase of 1,600,000 unregistered shares of its common stock, \$0.01 par value at a purchase price of \$1.25 per share. The

Company received \$2,000,000 in gross proceeds from the offering. The Company is using the net proceeds from this placement for general working capital purposes.

In connection with the placement, the Company also entered into a registration rights agreement with the investors, whereby the Company was obligated to file a registration statement with the Securities Exchange Commission on or before 90 calendar days after October 16, 2018 to register the resale by the investors of 1,600,000 shares of our common stock purchased in the placement. The registration statement was filed with the Securities and Exchange Commission on January 3, 2019 and Amendment No. 1 to the registration statement was filed with the Securities and Exchange Commission on January 16, 2019. The registration statement became effective on February 5, 2019.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q for the quarter and six months ended December 31, 2018 and with our audited consolidated financial statements for the year ended June 30, 2018 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 27, 2018.

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this report, the words “anticipate,” “suggest,” “estimate,” “plan,” “project,” “continue,” “ongoing,” “potential,” “expect,” “predict,” “believe,” “intend,” “may,” “will,” “should,” “could,” “would” and similar expressions are intended to identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described in this report, the risks described in our Annual Report on Form 10-K for the year ended June 30, 2018 and other reports we file with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made. We do not intend to update any of the forward-looking statements after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.

Overview

We have been developing and manufacturing advanced optical instruments since 1982. Today, the majority of our business is the design and manufacture of high-quality medical devices and 10% to 20% of our business is the design and manufacture of military and industrial products. Our medical instrumentation line includes traditional endoscopes and endocouplers as well as other custom imaging and illumination products for use in minimally invasive surgical procedures. Much of our recent development efforts have been targeted at the development of next generation endoscopes. During the last ten to fifteen years, we funded internal research and development programs to develop next generation capabilities for designing and manufacturing 3D endoscopes and very small Microprecision™ lenses, anticipating the surgical community’s future demand for smaller and more enhanced imaging systems for minimally invasive surgery. Over the last few years demand for these products has increased, and our engineering personnel resources and capabilities are now mostly consumed in revenue generating optical design and development projects for our customers.

Our unique proprietary technology in the areas of micro optical lenses and prisms, micro medical fiber and CMOS based cameras, and custom design of medical grade instruments, combined with recent developments in the areas of 3D displays, has allowed us to begin commercialization of related product and service offerings to a widening group of customers addressing various medical device, defense and aerospace applications. Thus, a portion of our revenues are now derived from engineering and design services we performed for our customers to incorporate our technologies

and capabilities into their medical device products. We believe that new products based on these technologies provide enhanced imaging for existing surgical procedures and can enable development of many new medical device products and related medical procedures.

We are registered to the ISO 9001:2015 and ISO 13485:2016 Quality Standards and comply with the FDA Good Manufacturing Practices and the European Union Medical Device Directive for CE marking of our medical products. Our internet website is www.poci.com. Information on our website is not intended to be integrated into this report.

The markets in which we do business are highly competitive and include both foreign and domestic competitors. Many of our competitors are larger and have substantially greater resources than we do. Furthermore, other domestic or foreign companies, some with greater financial resources than we have, may seek to produce products or services that compete with ours. We routinely outsource specialized materials and production efforts as required to obtain the most cost effective production.

We believe that competition for sales of our medical products and services, which have been principally sold to original equipment manufacturers, or OEM, customers, is based on our ability to design and produce technical features, performance, engineering service and production scheduling, on-time delivery, quality control and product reliability, and competitive pricing.

We believe that our future success depends to a large degree on our ability to develop new optical products and services to enhance the performance characteristics and methods of manufacture of existing products. Accordingly, we expect to continue to seek and obtain product-related design and development contracts with customers and to selectively invest our own funds on research and development, particularly in the areas of Microprecision™ optics, micro medical cameras and 3D endoscopes.

For the six months ended December 31, 2018, approximately 77% of our sales were made to seven customers. Of these, four were medium to large, international, medical device companies and one was a large defense contractor. Each of these customers has been our customer for numerous years. The other two customers were early-stage companies developing endoscopic products that incorporate our unique design capabilities. Sales to these seven customers included both products we developed over five years ago and products we are currently developing which rely heavily on our unique, proprietary Microprecision™ lens technology and optical visualization system expertise.

Current sales and marketing activities are intended to broaden awareness of the benefits of our new technology platforms, which we believe are ready for general application to medical device projects requiring surgery-grade visualization from sub-millimeter sized devices and 3D endoscopy. Successful engineering projects for us eventually transition to manufacturing orders as our customers bring their products to market. We market directly to established medical device companies primarily in the United States that we believe could benefit from our advanced endoscopy visualization systems. Through this direct marketing, referrals, attendance at trade shows including Medical Design and Manufacturing West (MD&M) and MD&M East, our objective is to maintain our pipeline of engineering projects with the potential for future growth from manufacturing orders, thereby increasing our overall revenues from a growing number of manufacturing medical device customers.

General

This management's discussion and analysis of financial condition and results of operations is based upon our unaudited consolidated financial statements, which have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes in our critical accounting policies as disclosed in the Notes to our Financial Statements contained in our Annual Report on Form 10-K for the year ended June 30, 2018 filed with the Securities and Exchange Commission on September 27, 2018.

Results of Operations

Our total revenues for the quarter ended December 31, 2018, were \$1,477,851, as compared to \$812,773 for the same period in the prior year, an increase of \$665,078, or 81.8%. Revenues were relatively unchanged in the components and engineering categories during the quarter ended December 31, 2018 compared to the same quarter of the prior year. Production revenues increased to \$933,143 during the quarter ended December 31, 2018, from \$244,323 during the same quarter of the prior year, an increase of \$688,820 or 282%. The majority of our revenues are derived from engineering design and manufacturing services related to products marketed or under development by our OEM customers. Therefore, our revenues are subject to fluctuations on a product by product basis from period to period.

Engineering projects continue to range in type and include CMOS, Microprecision™, 3D and robotic visualization and illumination systems. While the number of revenue generating engineering projects decreased from eighteen during the quarter ended December 31, 2017 to six during the quarter ended December 31, 2018, engineering design service revenues during the quarters ended December 31, 2018 and 2017 were \$318,741 and \$342,855, respectively. The slight decrease in engineering service revenue during the quarter ended December 31, 2018 when compared to the same quarter of the prior year was due primarily to a \$135,534 decrease caused by one project transitioning to production during fiscal year 2018, which was offset by a \$142,942 increase in engineering service revenue from one 3D robotic project in the quarter ended December 31, 2018 compared to revenue from that project in the same quarter of the prior year. Other increases and decreases in individual project revenues between the quarters are considered to be normal fluctuations for the types of development services provided to our customers.

The \$688,820 or 282% increase in production revenue during the quarter ended December 31, 2018 compared to the same quarter of the prior year resulted primarily from a \$572,016 increase in sales from two projects transitioned from engineering to production, plus a \$164,460 increase in revenue from a traditional spine product sold to a long-standing customer. The new production products represent a cardiovascular fiberoptic incorporating our Microprecision™ technology and an ENT scanning device incorporating CMOS and Microprecision™ technologies.

Our total revenues for the six months ended December 31, 2018 were \$3,037,309, as compared to \$1,841,519 for the same period in the prior year, an increase of \$1,195,790, or 64.9%. Engineering design service revenues increased by \$67,860 or 8.9% in the six months ended December 31, 2018 compared to the same quarter of the prior year, due primarily from decreases caused by the transition of two engineering projects to production offset by a larger increase of revenue from a 3D robotic engineering project during the six months ended December 31, 2018. Optical component revenues decreased \$145,162 or 21.7% during the six months ended December 31, 2018 compared to the same period of the prior year primarily due to decreases in one defense company project and a medical device repair catalogue company, partially offset by an increase in prisms sold to a medical device manufacturer during the six months ended December 31, 2018 compared to the same period of the prior year.

Production revenues increased during the six months ended December 31, 2018 compared to the same quarter of the prior year by \$1,273,092 or 311%. As in the quarter ended December 31, 2018, the increase in production revenue during the six month period ended December 31, 2018 compared to the same six month period of the prior year resulted primarily from a \$1,022,963 increase in sales from two projects transitioned from engineering to production, plus a \$173,146 increase in revenue from a traditional spine product sold to a long-standing customer. The new production products represent a cardiovascular fiberscope incorporating our Microprecision™ technology and an ENT scanning device incorporating CMOS and Microprecision™ technologies.

Gross profit for the quarter ended December 31, 2018 was \$355,722, compared to \$300,222 for the same period in the prior year, reflecting an increase of \$55,500, or 18.5%. Gross profit for the quarter ended December 31, 2018 as a percentage of our revenues was 24.1%, a decrease from the gross profit percentage of 36.9% for the same period in the prior year. Gross profit for the six months ended December 31, 2018 was \$818,229, as compared to \$686,964 for the same period in the prior year, which reflects an increase of \$131,265 or 19.1%. Gross profit for the six months ended December 31, 2018 as a percentage of our revenues was 26.9%, a decrease from the gross profit percentage of 37.3% for the same period in the prior year. Quarterly gross profit and gross profit percentage depend on a number of factors, including overall sales volume, facility utilization, product sales mix, the costs of engineering services, and production start up costs and challenges in connection with new products.

Although the higher level of revenues during the quarter and six month periods ended December 31, 2018 when compared to the same quarter and six month periods of the prior year absorbed a greater amount of fixed manufacturing costs thereby increasing realized gross margins, two projects encountered cost over-runs that were the primary cause of the decreased gross margins as a percentage of sales during the quarter and six months periods ended December 31, 2018. The two projects represent 27%-28% of total revenues for the quarter and six months ended December 31, 2018, one being a production project impacting the gross margin percentage by 3% and 4% in the quarter and six months ended December 31, 2018, respectively, and the other being an engineering service project impacting the gross margin percentage by 9% and 6% in the quarter and six months ended December 31, 2018, respectively. The cost over-runs in each of these cases resulted from design challenges and issues we are addressing and that we believe will only cause a temporary decrease in total realized gross margins. The remainder of our production and engineering jobs resulted in margins within our targeted range with reasonably expected fluctuations.

Research and development expenses were \$125,413 for the quarter ended December 31, 2018, compared to \$90,031 for the same period in the prior year, an increase of \$35,382, or 39.3%. Research and development expenses were \$226,211 for the six months ended December 31, 2018, compared to \$208,458 for the same period in the prior year, an increase of \$17,753, or 8.5%. In-house research and development and certain internal functions not directly related to customer engagements are classified as research and development expenses with the majority of our engineering, research and development activities being consumed in revenue generating engagements with our customers for the development of their products. The increase in research and development expenses during the quarter and six months ended December 31, 2018, compared to the same periods of the prior year, resulted from an increase of two engineering positions reflected in the six month period ended December 31, 2018 compared to the same period of the prior year when we were experiencing a temporary reduction in engineering department staffing. Consequently, the

amount of wages and related overhead costs not consumed in customer projects was higher during the periods ended December 31, 2018 when compared to the same periods of the prior year.

Selling, general and administrative expenses were \$1,016,405 for the six months ended December 31, 2018, compared to \$566,619 for the same period in the prior year, an increase of \$449,786, or 79.4%. The increase in the six months ended December 31, 2018, compared to the same period of the prior fiscal year was primarily due to increased non-cash stock-based compensation expense of \$320,184 relating to stock option and common stock awards. Selling, general and administrative expenses were further increased during the quarter ended December 31, 2018 when compared to the same quarter of the prior fiscal year by increased compensation costs for existing personnel, sales commissions, and shipping costs for increased production materials purchased from overseas, which were partially offset by a reduction in bad debt expense related to one isolated customer in the prior year and decreased fees paid to an investor relations firm.

Selling, general and administrative expenses were \$355,916 for the quarter ended December 31, 2018, compared to \$270,035 for the same period in the prior year, an increase of \$85,881, or 31.8%, resulting from increases in compensation costs for existing personnel, travel expenses, product liability insurance, and shipping costs for increased production materials purchased from overseas, which were partially offset by decreased fees paid to an investor relations firm.

No income tax provision was recorded in the quarter and six month periods ended December, 2018 and 2017 because of the losses generated in those periods.

Liquidity and Capital Resources

We have sustained recurring net losses for several years, although during the last three fiscal quarters our financial performance has improved somewhat. During the quarter and six month periods ended December 31, 2018, we incurred net losses of \$125,948 and \$425,233, respectively. We also incurred net losses of \$351,390 and \$1,006,457 during the fiscal years ended June 30, 2018 and 2017, respectively. Revenues during the quarters ended June 30, September 30, and December 31, 2018 have increased to \$1,460,932, \$1,559,458 and 1,477,851, respectively. Excluding expenses relating to non-cash stock-based compensation expenses and non-recurring bad debt expense non-GAAP net income was the following during the last three fiscal quarters:

	Fiscal Quarter Ended		
	June 30, 2018	September 30, 2018	December 31, 2018
Net income (loss)	\$ 16,992	\$(299,285)	\$(125,948)
Non-cash stock-based compensation	10,339	342,948	10,228
Non-recurring bad debt expense	113,750	–	–
Non-GAAP net income (loss)	\$ 141,081	\$ 43,663	\$(115,720)

As of December 31, 2018, cash and cash equivalents were \$1,744,644, accounts receivable were \$728,636, and current liabilities were \$1,383,496. Our working capital was \$2,321,826 and \$481,876 at December 31, 2018 and June 30, 2018, respectively, with the increase at December 31, 2018 resulting primarily from the recent sale of our common stock. As reported on Form 8-K filed with the Securities and Exchange Commission on October 18, 2018, we received \$2,000,000 from the sale of 1,600,000 shares of our common stock at \$1.25 per share, which we are using for general working capital purposes. Proceeds from this stock offering, combined with our recently improved financial performance, significantly enhances our working capital position and financial condition. Critical to our ability to maintain our financial condition is achieving a level of quarterly revenues at or greater than the levels achieved during the most recent three fiscal quarters as well as meeting targeted gross margins while limiting the growth of other operating expenses. A combination of lower revenue levels than experienced in the last three quarters, decreasing gross margins, or increasing operating expenses could result in the use of our cash and working capital and an overall decline in our current financial condition.

We have traditionally funded working capital needs through product sales, management of working capital components of our business, cash received from public and private offerings of our common stock, warrants to purchase shares of our common stock or convertible notes, and by customer advances paid against purchase orders by our customers and recorded in the current liabilities section of the accompanying financial statements. Our management believes that the opportunities represented by our current production projects and engineering pipeline of Microprecision™ optical elements, micro medical camera assemblies and 3D endoscope projects have the potential to generate increasing revenues and profitable financial results.

Capital equipment expenditures during the six months ended December 31, 2018 and 2017 were \$76,184 and \$0, respectively. Future capital equipment expenditures will be dependent upon the type and amount of future sales revenue and the needs of on-going research and development efforts.

We have contractual cash commitments related to open purchase orders as of December 31, 2018 of approximately \$402,000, including a \$19,156 commitment remaining under a five-year capital lease obligation for the acquisition of equipment (see Note 3. Capital Lease Obligation). We have no other contractual cash commitments since leased facilities are currently on a month-to-month basis.

On October 16, 2018, the Company entered into agreements with accredited investors for the sale and purchase of 1,600,000 unregistered shares of its common stock, \$0.01 par value at a purchase price of \$1.25 per share. The Company received \$2,000,000 in gross proceeds from the offering. The Company is using the net proceeds from this placement for general working capital purposes.

In connection with the placement, the Company also entered into a registration rights agreement with the investors, whereby the Company was obligated to file a registration statement with the Securities Exchange Commission on or before 90 calendar days after October 16, 2018 to register the resale by the investors of 1,600,000 shares of our common stock purchased in the placement. The registration statement was filed with the Securities and Exchange Commission on January 3, 2019 and Amendment No. 1 to the registration statement was filed with the Securities and Exchange Commission on January 16, 2019. The registration statement became effective on February 5, 2019.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Management's Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures, including internal control over financial reporting, were not effective, as of December 31, 2018, to ensure the information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (i) is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are intended to be designed to provide reasonable assurance that such information is accumulated and communicated to our management. Based on this evaluation, our management concluded that our internal control over financial reporting was not effective as of December 31, 2018.

The following is a description of two material weaknesses in our internal control over financial reporting:

Segregation of Duties: As previously disclosed in our Annual Reports on Form 10-K for the fiscal years ended June 30, 2008-2018, our management identified a control deficiency during the 2008 fiscal year because we lacked sufficient staff to segregate accounting duties. We believe the control deficiency resulted primarily because we have the equivalent of one and one-half persons performing all accounting-related on-site duties. As a result, we did not maintain adequate segregation of duties within our critical financial reporting applications, the related modules and financial reporting processes. This control deficiency could result in a misstatement of balance sheet and income statement accounts in our interim or annual consolidated financial statements that would not be detected. Accordingly, management has determined that this control deficiency constitutes a material weakness. During the period beginning with fiscal year 2008 through June 30, 2018, no audit adjustments resulting from this condition were required.

To address and remediate the material weakness in internal control over financial reporting described above, beginning with the quarter ended September 30, 2008, we instituted a procedure whereby our Chief Executive Officer, our Chief Financial Officer and other members of our Board of Directors perform a higher level review of the quarterly and annual reports on Form 10-Q and Form 10-K prior to filing.

We believe that the step outlined above strengthens our internal control over financial reporting and mitigates the material weakness described above. As part of our assessment of internal control over financial reporting for the fiscal year ended June 30, 2018, our management has evaluated this additional control and has determined that it is operating effectively.

Inventory Valuation: As previously disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2018, we reported a material weakness with respect to the valuation of our inventories. Specifically, the amounts used to value our inventory at June 30, 2009 with respect to overhead rates and purchased items were often inconsistent with the supporting documentation, due to year-to-year changes in overhead rates and costs of purchased items that were not properly reflected in inventory valuation. Accordingly, management had determined that this control deficiency constituted a material weakness as of June 30, 2009. Audit adjustments of approximately \$58,000 and \$41,000 to our audited financial statements as of June 30, 2011 and June 30, 2017, respectively, were necessary as a result of this condition.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the first quarter of our fiscal year covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

To address and remediate the material weakness in internal control over financial reporting described above, beginning in the quarter ended September 30, 2009 and continuing through the quarter ended December 31, 2018, we implemented processes to improve our inventory controls and documentation surrounding inventory valuation for overhead rates, and performed procedures to ensure that the pricing of inventory items was consistent with the supporting documentation. We believe that the step outlined above strengthens our internal control over financial reporting and mitigates the material weakness described above.

We intend to continue to remediate material weaknesses and enhance our internal controls but cannot guarantee that our efforts will result in remediation of our material weaknesses or that new issues will not be exposed in this process.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

Our Company, on occasion, may be involved in legal matters arising in the ordinary course of our business. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations. We are not aware of any pending or threatened litigation against us or our officers and directors in their capacity as such that could have a material impact on our operations or finances.

Item 1A. Risk Factors.

There have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2018, as filed with the Securities and Exchange Commission on September 27, 2018; and our quarterly report for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on November 14, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Other than as previously disclosed, we did not issue unregistered securities during the quarter ended December 31, 2018.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Description

- 2.1 Asset Purchase Agreement between the Company and Optometrics Corporation, dated January 18, 2008 (included as Exhibit 2.1 to the Form 8-K filed January 25, 2008, and incorporated herein by reference).
- 3.1 Articles of Organization of Precision Optics Corporation, Inc., as amended (included as Exhibit 3.1 to the Form SB-2 filed March 16, 2007, and incorporated herein by reference).
- 3.2 Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.2 to the Form S-1 filed December 18, 2008, and incorporated herein by reference).
- 3.3 Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated November 25, 2008 and effective December 11, 2008 (included as Exhibit 3.1 to the Form 8-K filed December 11, 2008, and incorporated herein by reference).
- 3.4 Amended and Restated Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.1 to the Current Report on Form 8-K filed July 11, 2014, and incorporated herein by reference).
- 10.1 Precision Optics Corporation, Inc. 2011 Equity Incentive Plan, dated October 13, 2011 (included as Exhibit 10.2 to Form S-8 filed October 14, 2011, and incorporated herein by reference.)
- 10.2 Precision Optics Corporation, Inc. Amended 2011 Equity Incentive Plan, dated October 14, 2011, as amended on April 16, 2015 (included as Exhibit 10.1 to the Company's Registration Statement on Form S-8 filed April 20, 2015, and incorporated herein by reference).
- 10.3 Consulting Agreement by and between the Company and Donald A. Major, dated June 15, 2016 (included as Exhibit 10.1 to the Form 8-K filed on June 23, 2016, and incorporated herein by reference).
- 10.4 Form of Securities Purchase Agreement, by and among the Company and the Investors, dated November 22, 2016 (included as Exhibit 10.1 to the Form 8-K filed November 29, 2016, and incorporated herein by reference).
- 10.5 Form of Registration Rights Agreement, by and among the Company and the Investors, dated November 22, 2016 (included as Exhibit 10.2 to the Form 8-K filed on November 29, 2016, and incorporated herein by reference).
- 10.6 Form of Securities Purchase Agreement, by and the Company and the Investors, dated August 22, 2017 (included as Exhibit 10.1 to the Form 8-K filed on August 25, 2017, and incorporated herein by reference).
- 10.7 Form of Registration Rights Agreement, by and among the Company and the Investors, dated August 22, 2017 (included as Exhibit 10.2 to the Form 8-K filed on August 25, 2017, and incorporated herein by reference).
- 10.8

Compensation Agreement, by and between the Company and Joseph N. Forkey, dated August 2, 2018 (included as Exhibit 10.1 to the Form 8-K filed on August 3, 2018, and incorporated herein by reference).

10.9 Offer letter by and between the Company and Donald A. Major, dated August 2, 2018 (included as Exhibit 10.9 to the Form 10-K filed on September 27, 2018, and incorporated herein by reference).

10.10 Form of Securities Purchase Agreement by and among the Company and the Investors, dated October 16, 2018 (included as Exhibit 10.1 to the Form 8-K filed on October 18, 2018, and incorporated herein by reference).

- 10.11 Form of Registration Rights Agreement by and among the Company and the Investors, dated October 16, 2018 (included as Exhibit 10.2 to the Form 8-K filed on October 18, 2018, and incorporated herein by reference).
- 14.1 Precision Optics Corporation, Inc. Corporate Code of Ethics and Conduct (included as Exhibit 14.1 to the Form 10-K filed September 28, 2008, and incorporated herein by reference).
- 21.1 Subsidiaries of the Registrant (included as Exhibit 21.1 to the Form 10-K filed September 26, 2008, and incorporated herein by reference).
- 31.1* Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2* Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1* Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS* XBRL Instance Document

101.SCH* XBRL Taxonomy Extension Schema Document

101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* XBRL Taxonomy Extension Definition Linkbase Document

101.LAB* XBRL Taxonomy Extension Label Linkbase Document

101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRECISION OPTICS CORPORATION, INC.

Date: February 12, 2019 By: /s/ Joseph N. Forkey
Joseph N. Forkey

Chief Executive Officer

(Principal Executive Officer)

Date: February 12, 2019 By: /s/ Donald A. Major
Donald A. Major
Chief Financial Officer

(Principal Financial Officer and Principal Accounting
Officer)